Clinical Trials
15 trialsNCT02680795 2025-10-20
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Acrotech Biopharma Inc.
Phase 1 Completed
NCT04703920 2025-01-23
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT04184869 2023-05-03
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01583777 2020-01-03
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01839097 2020-01-03
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01273155 2019-03-26
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00926640 2018-10-19
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00334789 2018-04-03
Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT02142530 2018-01-25
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
Massachusetts General Hospital
Phase 1 Completed
NCT01075425 2016-04-15
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Virginia Commonwealth University
Phase 1 Completed
NCT01317927 2015-09-23
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
Spectrum Pharmaceuticals, Inc
Phase 1 Completed
NCT00413075 2015-07-08
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Phase 1 Completed
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT00351975 2014-12-23
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
Phase 1 Completed
NCT00348985 2013-05-03
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed